Inhaler devices for chronic obstructive pulmonary disease: Insights from patients and healthcare practitioners

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 28, Issue 3, 2015, Pages 219-228

  Molimard, Mathieu ^a   Colthorpe, Paul ^b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

chronic obstructive pulmonary disease; healthcare practitioners' preference; inhaler devices; patient preference

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT;

ADULT; ARTICLE; BREATHING; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG SELF ADMINISTRATION; DRY POWDER INHALER; FRANCE; GERMANY; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; ITALY; JAPAN; METERED DOSE INHALER; MIDDLE AGED; NURSE; PATIENT PREFERENCE; PATIENT SATISFACTION; PHYSICIAN; UNITED KINGDOM; UNITED STATES; ATTITUDE TO HEALTH; CLINICAL TRIAL; DRUG EFFECTS; EQUIPMENT DESIGN; EUROPE; FEMALE; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; INHALATIONAL DRUG ADMINISTRATION; INTERNET; LUNG; MALE; MULTICENTER STUDY; NEBULIZER; PATHOPHYSIOLOGY; PATIENT SELECTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE;

ADMINISTRATION, INHALATION; ATTITUDE OF HEALTH PERSONNEL; BRONCHODILATOR AGENTS; EQUIPMENT DESIGN; EUROPE; FEMALE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNET; JAPAN; LUNG; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PATIENT PREFERENCE; PATIENT SELECTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84930445337     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2014.1142     Document Type: Article

References (34)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Available from: http://www.goldcopd.org. 2013. Accessed August 26, 2013.
2. World Health Organization. Chronic obstructive pulmonary disease (COPD). Available from http://www.who.int/ respiratory/copd/en/. 2013. Accessed July 10, 2013.
3. Mannino DM, and Kiriz VA: Changing the burden of COPD mortality. Int J Chron Obstruct Pulmon Dis. 2006;1: 219-233.
4. George J, Kong DC, and Stewart K: Adherence to disease management programs in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2007;2:253-262.
5. DiMatteo MR: Variations in patients' adherence to medical recommendations: A quantitative review of 50 years of research. Med Care. 2004;42:200-209.
6. Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, Sikkema-Ortiz J, Gardner DD, and Wilkins RL: Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008;3: 371-384.
7. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, Smaldone GC, and Guyatt G: Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127: 335-371.
8. Bateman ED: Improving inhaler use in COPD and the role of patient preference. Eur Respir Rev. 2005;14: 85-88.
9. Vincken W, Dekhuijzen PR, Barnes P: The ADMIT series - Issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J. 2010;19:10-20.
10. Newman SP: Inhaler treatment options in COPD. Eur Respir Rev. 2005;14:102-108.
11. Anderson P: Patient preference for and satisfaction with inhaler devices. Eur Respir Rev. 2005;14:109-116.
12. Makela MJ, Backer V, Hedegaard M, and Larsson K: Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107: 1481-1490.
13. Stevens N: Inhaler devices for asthma and COPD: choice and technique. Prof Nurse. 2003;18:641-645.
14. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, and Moore N: Assessment of handling of inhaler devices in real life: An observational study in 3811 patients in primary care. J Aerosol Med. 2003;16:249-254.
15. Molimard M, and Girogi-Vigo K: How can we improve patient use of inhaler devices in COPD? [Poster]Molimard M, Girogi-Vigo K. European Respiratory Society Annual Congress, 24-28 September, Amsterdam,The Netherlands. 2011.
16. Sawtooth Software. Conjoint Analysis (http://www.saw toothsoftware.com/solutions/conjoint-analysis). 2010. Accessed August 1, 2013.
17. Sawtooth Software. Adaptive choice-based conjoint analysis (http://www.sawtoothsoftware.com/products/acbc). 2010. Accessed August 1, 2013.
18. Sawtooth Software. Choice-based conjoint analysis (http:// www.sawtoothsoftware.com/products/cbc). 2010. Accessed August 1, 2013.
19. Schulte M, Osseiran K, Betz R,Wencker M, Brand P, Meyer T, and Haidl P: Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv. 2008;21:321-328.
20. Hodder R, and Price D: Patient preferences for inhaler devices in chronic obstructive pulmonary disease: Experience with Respimat Soft Mist inhaler. Int J Chron Obstruct Pulmon Dis. 2009;4:381-390.
21. Clark AR, and Hollingworth AM: The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - Implications for in vitro testing. J Aerosol Med. 1993;6:99-110.
22. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbetta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, and Crompton GK: Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102:593-604.
23. Wilson DS, Gillion MS, and Rees PJ: Use of dry powder inhalers in COPD. Int J Clin Pract. 2007;61:2005-2008.
24. van der Palen J, Klein JJ, Kerkhoff AH, and van Herwaarden CL: Evaluation of the effectiveness of four different inhalers in patients with chronic obstructive pulmonary disease. Thorax. 1995;50:1183-1187.
25. Fink JB, and Rubin BK: Problems with inhaler use: A call for improved clinician and patient education. Respir Care. 2005;50:1360-1374.
26. Bourbeau J, and Bartlett SJ: Patient adherence in COPD. Thorax. 2008;63:831-838.
27. Yu AP, Guerin A, Ponce de LD, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, and Setyawan J: Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: Multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14:486-496.
28. Geller DE: Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care. 2005;50:1313-1321.
29. Melani AS, Bracci LS, and Rossi M: Reduced peak inspiratory effort through the Diskus((R)) and the Turbuhaler(( R)) due to mishandling is common in clinical practice. Clin Drug Investig. 2005;25:543-549.
30. Jarvis S, Ind PW, and Shiner RJ: Inhaled therapy in elderly COPD patients; Time for re-evaluation? Age Ageing. 2007; 36:213-218.
31. Broeders ME, Sanchis J, Levy ML, Crompton GK, and Dekhuijzen PN: The ADMIT series - Issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Prim Care Respir J. 2009;18:76-82.
32. Hanania NA, Wittman R, Kesten S, and Chapman KR: Medical personnel's knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest. 1994;105: 111-116.
33. Nikander K: Challenges and opportunities in respiratory drug delivery devices. Expert Opin Drug Deliv. 2010;7: 1235-1238.
34. Yawn BP, Colice GL, and Hodder R: Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2012;7:495-502.